Literature DB >> 32220406

Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future.

Ali Jalali1, Danielle A Ryan2, Kathryn E McCollister3, Lisa A Marsch4, Bruce R Schackman2, Sean M Murphy2.   

Abstract

Economic evaluations provide evidence that informs stakeholders on how to efficiently allocate real and financial healthcare resources. The purpose of this study was to review and discuss the integration of economic evaluations into the National Drug Abuse Treatment Clinical Trials Network (CTN) since its inception, as well as expectations for the future of this relationship. A systematic review was performed on published and planned CTN economic evaluations in the CTN dissemination library and PubMed. The well-established Drummond checklist was used to evaluate the comprehensiveness and methodological rigor of published articles. One hundred thirty-eight ancillary, follow-up, or original protocols were reviewed, and 78 potentially relevant published articles were identified. A total number of 14 protocols included an economic evaluation. Of these, 6 protocols were completed, 2 were reported as active, and 6 were reported as in-development at the time of this review. Of the 78 published articles, 9 met the inclusion criteria. As gauged by the Drummond checklist, the quality of CTN published economic evaluations were found to improve over time, and recent published articles were identified as guides to cutting-edge economic research. As the CTN continues to grow and mature, it is imperative that high-quality economic evaluations are incorporated alongside trials in order to maximize the public health impact of the CTN.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32220406      PMCID: PMC7293894          DOI: 10.1016/j.jsat.2020.02.002

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  40 in total

Review 1.  The death of cost-minimization analysis?

Authors:  A H Briggs; B J O'Brien
Journal:  Health Econ       Date:  2001-03       Impact factor: 3.046

2.  What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

Authors:  R Scott Braithwaite; David O Meltzer; Joseph T King; Douglas Leslie; Mark S Roberts
Journal:  Med Care       Date:  2008-04       Impact factor: 2.983

Review 3.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

4.  How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings.

Authors:  Paul G Farnham; Stephanie L Sansom; Angela B Hutchinson
Journal:  Med Decis Making       Date:  2012-01-12       Impact factor: 2.583

Review 5.  Cost-Effectiveness Analyses in Orthopaedic Surgery: Raising the Bar.

Authors:  Prashant V Rajan; Rameez A Qudsi; Lindsey L Wolf; Elena Losina
Journal:  J Bone Joint Surg Am       Date:  2017-07-05       Impact factor: 5.284

6.  Costs of HIV prevention among out-of-treatment drug-using women: results of a randomized controlled trial.

Authors:  Jennifer Prah Ruger; Arbi Ben Abdallah; Linda Cottler
Journal:  Public Health Rep       Date:  2010 Jan-Feb       Impact factor: 2.792

7.  Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.

Authors:  Benjamin P Linas; Angela Y Wong; Bruce R Schackman; Arthur Y Kim; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2012-04-04       Impact factor: 9.079

8.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

9.  Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial.

Authors:  Sean M Murphy; Aimee N C Campbell; Udi E Ghitza; Tiffany L Kyle; Genie L Bailey; Edward V Nunes; Daniel Polsky
Journal:  Drug Alcohol Depend       Date:  2016-01-30       Impact factor: 4.492

10.  Cost-effectiveness of prize-based contingency management in methadone maintenance treatment programs.

Authors:  Jody L Sindelar; Todd A Olmstead; Jessica M Peirce
Journal:  Addiction       Date:  2007-07-23       Impact factor: 6.526

View more
  3 in total

1.  Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.

Authors:  Ali Jalali; Philip J Jeng; Daniel Polsky; Sabrina Poole; Yi-Chien Ku; George E Woody; Sean M Murphy
Journal:  J Subst Abuse Treat       Date:  2022-07-02

2.  Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial.

Authors:  Ali Jalali; Danielle A Ryan; Philip J Jeng; Kathryn E McCollister; Jared A Leff; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman; Sean M Murphy
Journal:  Drug Alcohol Depend       Date:  2020-08-05       Impact factor: 4.492

3.  Health economic analyses of the justice community opioid innovation network (JCOIN).

Authors:  Sean M Murphy; Neda Laiteerapong; Mai T Pho; Danielle Ryan; Iván Montoya; Theresa I Shireman; Elbert Huang; Kathryn E McCollister
Journal:  J Subst Abuse Treat       Date:  2021-01-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.